CTC immune escape mediated by PD-L1

被引:37
|
作者
Wang, Xuefei
Sun, Qiang
Liu, Qiaofei
Wang, Changjun
Yao, Ru
Wang, Yimin
机构
[1] Chinese Acad Med Sci, Breast Surg Dept, Beijing, Peoples R China
[2] Peking Union Med Coll, Peking Union Med Coll & Hosp, Beijing, Peoples R China
[3] Shanxi Prov Peoples Hosp, Xian, Shaanxi, Peoples R China
关键词
BREAST-CANCER; CELLS; SUPPRESSION;
D O I
10.1016/j.mehy.2016.05.022
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Breast cancer is the most common malignant tumor in women around the world. Most breast cancer related deaths are from CTC (circulating tumor cells) metastasis. CTC is associated with the breast cancer patients' prognosis. But recently, circulating clusters were found and its metastasis and tumor formation ability is 23-50 times as CTC. However, its mechanism has not been clarified. These days, researchers have successfully completed CTC cluster separation, CTC cell culture, and PD-L1 was found to be related with histological grading of tumor. Meanwhile, the high expression of PD-L1 in CTC surface has also been reported. Since PD-L1 can mediate Treg to play the role of immunosuppression, we propose that CTC with positive PD-L1 is easier to connect PD-L1, immune cells (Treg regulatory T cells, MDSC bone marrow inhibitory cells) and CM cytokines etc. On one hand, Treg cells can protect CTC from being attacked by the immune system through the immunosuppression, on the other hand, they can weaken CTL killing ability and trigger more MDSC. Finally, CTC formed the metastatic lesion. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:138 / 139
页数:2
相关论文
共 50 条
  • [31] Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
    Yuan, Keyu
    Wu, Jiangping
    Zhao, Yanjie
    Lyu, Shuzhen
    Zhou, Quan
    Shi, Feng
    Li, Yanping
    Song, Qingkun
    DIAGNOSTIC PATHOLOGY, 2022, 17 (01)
  • [32] Comparison o PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
    Yokoyama, Shintaro
    Miyoshi, Hiroaki
    JOURNAL OF THORACIC DISEASE, 2020, 12 (12) : 7553 - 7560
  • [33] Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer
    Alkhayyal, Noura
    Elemam, Noha M.
    Hussein, Amal
    Magdub, Sulaman
    Jundi, Majd
    Maghazachi, Azzam A.
    Talaat, Iman M.
    Bendardaf, Riyad
    HELIYON, 2022, 8 (09)
  • [34] Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
    Wu, Bogang
    Sun, Xiujie
    Gupta, Harshita B.
    Yuan, Bin
    Li, Jingwei
    Ge, Fei
    Chiang, Huai-Chin
    Zhang, Xiaowen
    Zhang, Chi
    Zhang, Deyi
    Yang, Jing
    Hu, Yanfen
    Curiel, Tyler J.
    Li, Rong
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [35] Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer
    Tanaka, Tsutomu
    Kutomi, Goro
    Kajiwara, Toshimitsu
    Kukita, Kazuharu
    Kochin, Vitaly
    Kanaseki, Takayuki
    Tsukahara, Tomohide
    Hirohashi, Yoshihiko
    Torigoe, Toshihiko
    Okamoto, Yoshiharu
    Hirata, Koichi
    Sato, Noriyuki
    Tamura, Yasuaki
    ONCOTARGET, 2017, 8 (15) : 24706 - 24718
  • [36] The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
    Berry, Diana
    Moldoveanu, Dan
    Rajkumar, Shivshankari
    Lajoie, Mathieu
    Lin, Tiffany
    Tchelougou, Damehan
    Sakthivel, Samridhi
    Sharon, Itai
    Bernard, Antoine
    Pelletier, Sandy
    Ripstein, Yael
    Spatz, Alan
    Miller, Wilson H.
    Jamal, Rahima
    Lapointe, Rejean
    Mes-Masson, Anne-Marie
    Petrecca, Kevin
    Meguerditchian, Ari-Nareg
    Richardson, Keith
    Wang, Beatrice
    Chergui, May
    Guiot, Marie-Christine
    Watters, Kevin
    Stagg, John
    Schmeing, T. Martin
    Rodier, Francis
    Turcotte, Simon
    Mihalcioiu, Catalin
    Meterissian, Sarkis
    Watson, Ian R.
    CELL REPORTS, 2025, 44 (03):
  • [37] Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals
    Lee, Dae Young
    Im, Eunji
    Yoon, Dahye
    Lee, Young-Seob
    Kim, Geum-Soog
    Kim, Donghwi
    Kim, Sung-Hoon
    SEMINARS IN CANCER BIOLOGY, 2022, 86 : 1033 - 1057
  • [38] PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
    Dosset, Magalie
    Vargas, Thaiz Rivera
    Lagrange, Anais
    Boidot, Romain
    Vegran, Frederique
    Roussey, Aurelie
    Chalmin, Fanny
    Dondaine, Lucile
    Paul, Catherine
    Marie-Joseph, Elodie Lauret
    Martin, Francois
    Ryffel, Bernhard
    Borg, Christophe
    Adotevi, Olivier
    Ghiringhelli, Francois
    Apetoh, Lionel
    ONCOIMMUNOLOGY, 2018, 7 (06):
  • [39] Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment
    Kwantwi, Louis Boafo
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (07) : 3077 - 3091
  • [40] PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
    Jin, Menglei
    Fang, Jun
    Peng, Junwen
    Wang, Xintian
    Xing, Ping
    Jia, Kunpeng
    Hu, Jianming
    Wang, Danting
    Ding, Yuxin
    Wang, Xinyu
    Li, Wenlu
    Chen, Zhigang
    MOLECULAR CANCER, 2024, 23 (01)